Author
Tracey Weisberg
Bio: Tracey Weisberg is an academic researcher. The author has contributed to research in topics: Breast cancer & Progesterone receptor. The author has an hindex of 3, co-authored 6 publications receiving 273 citations.
Papers
More filters
Stanford University1, Intermountain Healthcare2, The Royal Marsden NHS Foundation Trust3, American Society of Clinical Oncology4, University of North Carolina at Chapel Hill5, St. Jude Medical Center6, University of Michigan7, University of Queensland8, University of Texas MD Anderson Cancer Center9, Harvard University10, Yale Cancer Center11, Saskatchewan Health12, University of Saskatchewan13, Cornell University14, European Institute of Oncology15, University of Milan16, Johns Hopkins University17
TL;DR: The Expert Panel continues to recommend ER testing of invasive breast cancers by validated immunohistochemistry as the standard for predicting which patients may benefit from endocrine therapy, and no other assays are recommended for this purpose.
Abstract: PURPOSETo update key recommendations of the American Society of Clinical Oncology/College of American Pathologists estrogen (ER) and progesterone receptor (PgR) testing in breast cancer guideline.M...
510 citations
Stanford University1, Intermountain Healthcare2, The Royal Marsden NHS Foundation Trust3, American Society of Clinical Oncology4, University of North Carolina at Chapel Hill5, St. Jude Medical Center6, University of Michigan7, University of Queensland8, University of Texas MD Anderson Cancer Center9, Harvard University10, Yale Cancer Center11, University of Saskatchewan12, Saskatchewan Health13, Cornell University14, European Institute of Oncology15, University of Milan16, Johns Hopkins University17
TL;DR: The Expert Panel continues to recommend ER testing of invasive breast cancers by validated immunohistochemistry as the standard for predicting which patients may benefit from endocrine therapy, and no other assays are recommended for this purpose.
Abstract: Purpose.— To update key recommendations of the American Society of Clinical Oncology/College of American Pathologists estrogen receptor (ER) and progesterone receptor (PgR) testing in breast cancer...
175 citations
TL;DR: A 59-year-old woman of French-Canadian ancestry, with a family history of breast cancer and a documented BRCA2 mutation in a first-degree relative, sought care for a 5-month history of a 1-cm, raised, and erythematous mass lateral to the left labium majus.
Abstract: Case Report A 59-year-old woman of French-Canadian ancestry, with a family history of breast cancer and a documented BRCA2 mutation in a first-degree relative, sought care for a 5-month history of a 1-cm, raised, and erythematous mass lateral to the left labium majus. Excisional biopsy results revealed infiltrating mammary adenocarcinoma with mucinous differentiation (Fig 1A). The tumor cells were positive for cytokeratin 7 (CK7), mammoglobin (Fig 1B), estrogen receptor (90%; Fig 1C), and progesterone receptor (30%), and were negative for CK20, Wilms tumor 1, gross cystic disease fluid protein 15, and human epidermal growth factor receptor 2 (HER2)/neu (1 ). The tumor infiltrated through the epithelium, and specimen biopsy margins were focally positive. She had undergone total abdominal hysterectomy and bilateral salpingo-oophorectomy at age 51 years because of abnormal vaginal bleeding. Pathology was nondiagnostic. She was without a history of breast problems and had regular mammograms in the past. On referral to gynecologic oncology, a minimal scar without underlying mass was noted at the biopsy site. Otherwise, physical examination, including examination of the breasts and the remainder of the external genitalia, anus, and inguinal regions was negative for clinical evidence of malignancy.Breastmagneticresonanceimaging,bodycomputedtomography, and bone scan were nondiagnostic. She underwent a radical local vulvar excision of the scar with left inguinofemoral lymphadenectomy. There was no residual tumor noted in the vulva, and left groin lymph nodes were negative. Following an uneventful postoperative course, she was started on tamoxifen, 20 mg daily. Her family history was significant for breast cancer in her sister at age 59 years, and her mother’s history of bilateral breast cancer at ages 39 and 49 years (Fig 2). A close relative had previously undergone comprehensive BRCA analysis. This result returned with a BRCA2 mutation (8765delAG) that is a founder mutation in breast and ovarian cancer families of French-Canadian descent. Following her final surgery, the patient underwent single-site testing for this BRCA2 mutation and was found to be positive.
8 citations
TL;DR: In this article, phase-specific survivorship care plans (SCPs) have been proposed to provide individualized, comprehensive survivorship, particularly in terms of care coordination and transition, if used as dynamic documents.
4 citations
TL;DR: It is shown that it is possible for an ASCO State Affiliate to sponsor and develop a Collaborative Improvement Network (CIN), in which experienced practices mentor inexperienced practices in QOPI and practices benchmark results against each other, sharing best practices.
Abstract: 79 Background: Participation in the Quality Oncology Practice Initiative (QOPI) by members of the Northern New England Oncology Society (NNECOS) has been historically low (two practices consistently participating). A survey of members identified a lack of resources (time, personnel, financial) as the principal obstacles. In alignment with NNECOS’ mission “To assure the availability of and access to high quality oncology care in our region,” NNECOS sought to determine if it could establish a Collaborative Improvement Network (CIN) in which 1) experienced practices mentor inexperienced practices in QOPI, and 2) practices benchmark results against each other, sharing best practices. Methods: Six practices from the NNECOS member states of Maine, New Hampshire, and Vermont agreed to join the CIN and participate in the fall 2010 and spring 2011 QOPI data collection. Meetings were held following each QOPI data collection and blinded results were compared. High achievers on individual metrics shared their process...
1 citations
Cited by
More filters
Johns Hopkins University1, University of Utah2, Stanford University3, American Society of Clinical Oncology4, Ontario Institute for Cancer Research5, University of Sydney6, University of Nottingham7, St. Jude Medical Center8, University of Toronto9, Mayo Clinic10, University of Southern California11, Indiana University12, National Institutes of Health13, The Royal Marsden NHS Foundation Trust14
TL;DR: In this article, the authors updated key recommendations of the American Society of Clinical Oncology (ASCO)/College of American Pathologists (CAP) human epidermal growth factor receptor 2 (HER2) testing in breast cancer.
Abstract: Purpose.— To update key recommendations of the American Society of Clinical Oncology (ASCO)/College of American Pathologists (CAP) human epidermal growth factor receptor 2 (HER2) testing in breast ...
652 citations
TL;DR: The content featured in this issue focuses on the recommendations for overall management of ductal carcinoma in situ and the workup and locoregional management of early stage invasive breast cancer.
Abstract: The therapeutic options for patients with noninvasive or invasive breast cancer are complex and varied. These NCCN Clinical Practice Guidelines for Breast Cancer include recommendations for clinical management of patients with carcinoma in situ, invasive breast cancer, Paget disease, phyllodes tumor, inflammatory breast cancer, and management of breast cancer during pregnancy. The content featured in this issue focuses on the recommendations for overall management of ductal carcinoma in situ and the workup and locoregional management of early stage invasive breast cancer. For the full version of the NCCN Guidelines for Breast Cancer, visit NCCN.org.
187 citations
01 Nov 2015
TL;DR: Among patients with hormone-receptor-positive, HER2-negative, axillary node-negative breast cancer who met established guidelines for the recommendation of adjuvant chemotherapy on the basis of clinicopathologic features, those with tumors that had a favorable gene-expression profile had very low rates of recurrence at 5 years with endocrine therapy alone.
Abstract: BACKGROUND
Prior studies with the use of a prospective-retrospective design including archival tumor samples have shown that gene-expression assays provide clinically useful prognostic information. However, a prospectively conducted study in a uniformly treated population provides the highest level of evidence supporting the clinical validity and usefulness of a biomarker.
METHODS
We performed a prospective trial involving women with hormone-receptor-positive, human epidermal growth factor receptor type 2 (HER2)-negative, axillary node-negative breast cancer with tumors of 1.1 to 5.0 cm in the greatest dimension (or 0.6 to 1.0 cm in the greatest dimension and intermediate or high tumor grade) who met established guidelines for the consideration of adjuvant chemotherapy on the basis of clinicopathologic features. A reverse-transcriptase-polymerase-chain-reaction assay of 21 genes was performed on the paraffin-embedded tumor tissue, and the results were used to calculate a score indicating the risk of breast-cancer recurrence; patients were assigned to receive endocrine therapy without chemotherapy if they had a recurrence score of 0 to 10, indicating a very low risk of recurrence (on a scale of 0 to 100, with higher scores indicating a greater risk of recurrence).
RESULTS
Of the 10,253 eligible women enrolled, 1626 women (15.9%) who had a recurrence score of 0 to 10 were assigned to receive endocrine therapy alone without chemotherapy. At 5 years, in this patient population, the rate of invasive disease-free survival was 93.8% (95% confidence interval [CI], 92.4 to 94.9), the rate of freedom from recurrence of breast cancer at a distant site was 99.3% (95% CI, 98.7 to 99.6), the rate of freedom from recurrence of breast cancer at a distant or local-regional site was 98.7% (95% CI, 97.9 to 99.2), and the rate of overall survival was 98.0% (95% CI, 97.1 to 98.6).
CONCLUSIONS
Among patients with hormone-receptor-positive, HER2-negative, axillary node-negative breast cancer who met established guidelines for the recommendation of adjuvant chemotherapy on the basis of clinicopathologic features, those with tumors that had a favorable gene-expression profile had very low rates of recurrence at 5 years with endocrine therapy alone. (Funded by the National Cancer Institute and others; ClinicalTrials.gov number, NCT00310180.).
158 citations
TL;DR: Clinical trials in the management of TNBC are discussed as well as perspectives for potential future treatments and various new agents and combination strategies have been explored.
Abstract: Triple‑negative breast cancer (TNBC) accounts for 10‑15% of all breast cancer cases. TNBCs lack estrogen and progesterone receptors and express low levels of HER2, and therefore do not respond to hormonal or anti‑HER2 therapies. TNBC is a particularly aggressive form of breast cancer that generally displays poorer prognosis compared to other breast cancer subtypes. TNBC is chemotherapy sensitive, and this treatment remains the standard of care despite its limited benefit. Recent advances with novel agents have been made for specific subgroups with PD‑L1+ tumors or germline Brca‑mutated tumors. However, only a fraction of these patients responds to immune checkpoint or PARP inhibitors and even those who do respond often develop resistance and relapse. Various new agents and combination strategies have been explored to further understand molecular and immunological aspects of TNBC. In this review, we discuss clinical trials in the management of TNBC as well as perspectives for potential future treatments.
134 citations